The pipeline of Hepatocellular Carcinoma is very robust, many potential therapies are being investigated for the treatment of Hepatocellular Carcinoma, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
Some of the leading pharma and biotech giants such as H3 Biomedicine, Genoscience Pharma, Kymab, Sanofi, Exelixis, and various others are involved in developing therapies for Hepatocellular Carcinoma. Of the emerging therapies and combination therapies, one of the most anticipated products to get launched is cabozantinib in combination with atezolizumab. Apart from this, several other molecules are in the mid to late stages, such as DKN-01, Cabozantinib S-malate with Pembrolizumab, H3B-6527, and others.
DelveInsight’s “Hepatocellular Carcinoma (HCC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hepatocellular Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Hepatocellular Carcinoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hepatocellular Carcinoma (HCC): An Overview
Hepatocellular Carcinoma (HCC) is defined as a liver tumor not eligible for local therapies given the extent of the disease or liver tumors that recur after local therapies. Patients with advanced Hepatocellular Carcinoma (HCC) usually have significant underlying liver disease, which is associated with poor tolerability to systemic chemotherapy.
Cancer may have spread to nearby lymph nodes and to distant sites within the body. Hepatocellular Carcinoma doesn’t often metastasize, but when it does, it’s most likely to spread to the lungs and bones. These cancers are widespread; they cannot be removed with surgery. Signs and symptoms are not always directly related to the stage of cancer; the effects of the disease are highly individualized for each person, and the following are some of the symptoms occurred in individuals Gynecomastia, Erythrocytosis, High cholesterol, Hypercalcemia, Hypoglycemia.
Hepatocellular Carcinoma (HCC) Market Key Facts
According to Surveillance, Epidemiology, and End Results (SEER), in the US, the incidence rate of Hepatocellular Carcinoma and Intrahepatic bile duct cancer was 9.0 per 100,000 which is estimated to be around 42,230 newly diagnosed cases in 2021, and the mortality rate was 6.6 per 100,000 per year, and the 5-year survival rate was 20.3%. Of them, the stage-wise incident cases of Hepatocellular Carcinoma and intrahepatic bile duct cancer were localized (45%), Regional (26%), Distant (18%), and Unknown (11%).
According to the Global Cancer Observatory, in the 7MM, the ASR incident rate of liver cancer is 7.4/100,000, which is estimated to be around 135,533 new cases in 2020, and the ASR mortality rate of liver cancer is 4.8/100,000, which is estimated to be around 100,793 number of deaths in 2020.
On November 2, 2022, Omega Therapeutics, Inc. (“Omega”) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OTX-2002, the company’s first-in-class epigenomic controller engineered to downregulate c-Myc (MYC), for the treatment of hepatocellular carcinoma (HCC).
On October 19, 2022, Tvardi Therapeutics, Inc. (“Tvardi”) announced that its lead product, TTI-101, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma (HCC).
On October 11, 2022, Elevar Therapeutics announced a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for its investigational drug rivoceranib in combination with camrelizumab as a treatment option for hepatocellular carcinoma (HCC).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hepatocellular Carcinoma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Hepatocellular Carcinoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hepatocellular Carcinoma (HCC) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Hepatocellular Carcinoma Epidemiology Segmented by –
Total Incident Cases of Hepatocellular Carcinoma in the 7MM (2019-32)
Total Treated Cases of Hepatocellular Carcinoma in the 7MM (2019-32)
Stage-wise patients of Hepatocellular Carcinoma in the 7MM (2019-32)
Hepatocellular Carcinoma (HCC) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatocellular Carcinoma market or expected to be launched during the study period. The analysis covers the Hepatocellular Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hepatocellular Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Hepatocellular Carcinoma Market Will Evolve and Grow by 2032 @
Hepatocellular Carcinoma (HCC) Therapeutics Analysis
There are currently six FDA-approved immunotherapy options for Hepatocellular Carcinoma. Several other immunotherapies are currently being tested in Hepatocellular Carcinoma clinical trials, including oncolytic viruses and adoptive cell therapy. Hence, the therapy market also includes AVASTIN (bevacizumab), a targeted antibody that targets the VEGF-A pathway; approved, in combination with atezolizumab, as a first-line treatment for subsets of patients with advanced Hepatocellular Carcinoma.
Pharmaceutical companies are working toward developing potential therapies for Hepatocellular Carcinoma (HCC) to fulfill the unmet medical needs of the currently used therapeutics. There are approx. 80+ key companies which are developing therapies for Hepatocellular Carcinoma. Currently, Sinocelltech is leading the therapeutics market with its Hepatocellular Carcinoma drug candidates in the most advanced stage of clinical development among all the key players.
The Leading Companies in the Hepatocellular Carcinoma (HCC) Therapeutics Market Include:
Taizhou Hanzhong Pharmaceuticals
Eli Lilly and Company
Shanghai Henlius Biotech
Jiangsu Hengrui Medicine
And Many More
Hepatocellular Carcinoma (HCC) Therapies Covered in the Report Include:
Tivozanib: AVEO Oncology
H3B-6527: H3 Biomedicine
GNS561: Genoscience Pharma
SAR445256 (also known as Alomfilimab, and formerly as KY1044): Kymab and Sanofi
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hepatocellular Carcinoma Competitive Intelligence Analysis
4. Hepatocellular Carcinoma Market Overview at a Glance
5. Hepatocellular Carcinoma Disease Background and Overview
6. Hepatocellular Carcinoma Patient Journey
7. Hepatocellular Carcinoma Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Hepatocellular Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Hepatocellular Carcinoma Unmet Needs
10. Key Endpoints of Hepatocellular Carcinoma Treatment
11. Hepatocellular Carcinoma Marketed Products
12. Hepatocellular Carcinoma Emerging Drugs and Latest Therapeutic Advances
13. Hepatocellular Carcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Hepatocellular Carcinoma Market Outlook (In US, EU5, and Japan)
16. Hepatocellular Carcinoma Access and Reimbursement Overview
17. KOL Views on the Hepatocellular Carcinoma Market
18. Hepatocellular Carcinoma Market Drivers
19. Hepatocellular Carcinoma Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
“Hepatocellular Carcinoma Pipeline Insight, 2023” report provides comprehensive insights about 80+ companies and 80+ drugs in the Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States